Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family
Debiopharm granted exclusive global rights to use Genome & Company’s antibodies to develop potential first-in-class ADCs integrating Debiopharm’s Multilink™ technology....




















